Immix Biopharma, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 11400 WEST OLYMPIC BLVD., LOS ANGELES, CA, 90064
Mailing Address 10573 W. PICO BLVD., LOS ANGELES, CA, 90064
Phone (888) 958-1084
Fiscal Year End 1231
EIN 454869378
Financial Overview
FY2025
-$21.61M
Net Income
$11.04M
Total Liabilities
$93.93M
Cash & Equivalents
$-0.76
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 10-K/A Annual report amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 10-K Annual financial report | March 25, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 25, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 20, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
Annual Reports
10-K March 25, 2026
- Lead drug NXC-201 showed a 75% complete response rate in AL Amyloidosis patients.
- FDA granted 'Breakthrough Therapy' status to NXC-201, accelerating the review path.
Insider Trading
BUY 2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.